OptiNose (OPTN) Competitors $0.42 0.00 (-0.45%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends OPTN vs. AMLX, ITOS, LFCR, BNTC, FHTX, ELDN, URGN, RZLT, AVIR, and LRMRShould you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include Amylyx Pharmaceuticals (AMLX), iTeos Therapeutics (ITOS), Lifecore Biomedical (LFCR), Benitec Biopharma (BNTC), Foghorn Therapeutics (FHTX), Eledon Pharmaceuticals (ELDN), UroGen Pharma (URGN), Rezolute (RZLT), Atea Pharmaceuticals (AVIR), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry. OptiNose vs. Amylyx Pharmaceuticals iTeos Therapeutics Lifecore Biomedical Benitec Biopharma Foghorn Therapeutics Eledon Pharmaceuticals UroGen Pharma Rezolute Atea Pharmaceuticals Larimar Therapeutics OptiNose (NASDAQ:OPTN) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations. Does the media refer more to OPTN or AMLX? In the previous week, Amylyx Pharmaceuticals had 6 more articles in the media than OptiNose. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 0 mentions for OptiNose. Amylyx Pharmaceuticals' average media sentiment score of 0.99 beat OptiNose's score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment OptiNose Neutral Amylyx Pharmaceuticals Positive Do analysts prefer OPTN or AMLX? OptiNose presently has a consensus price target of $3.00, indicating a potential upside of 614.12%. Amylyx Pharmaceuticals has a consensus price target of $7.33, indicating a potential upside of 81.07%. Given OptiNose's stronger consensus rating and higher possible upside, research analysts plainly believe OptiNose is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OptiNose 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Amylyx Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.56 Does the MarketBeat Community prefer OPTN or AMLX? OptiNose received 214 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 66.00% of users gave Amylyx Pharmaceuticals an outperform vote while only 63.50% of users gave OptiNose an outperform vote. CompanyUnderperformOutperformOptiNoseOutperform Votes24763.50% Underperform Votes14236.50% Amylyx PharmaceuticalsOutperform Votes3366.00% Underperform Votes1734.00% Which has stronger valuation & earnings, OPTN or AMLX? Amylyx Pharmaceuticals has higher revenue and earnings than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOptiNose$75.67M0.84-$35.48M-$0.28-1.50Amylyx Pharmaceuticals$196.49M1.41$49.27M-$3.82-1.06 Is OPTN or AMLX more profitable? Amylyx Pharmaceuticals has a net margin of -17.86% compared to OptiNose's net margin of -41.16%. OptiNose's return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets OptiNose-41.16% N/A -27.42% Amylyx Pharmaceuticals -17.86%-36.97%-29.61% Which has more volatility & risk, OPTN or AMLX? OptiNose has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Do insiders & institutionals have more ownership in OPTN or AMLX? 85.6% of OptiNose shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 2.3% of OptiNose shares are owned by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryAmylyx Pharmaceuticals beats OptiNose on 11 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get OptiNose News Delivered to You Automatically Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPTN vs. The Competition Export to ExcelMetricOptiNosePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.36M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.5010.5991.3417.19Price / Sales0.84195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book-0.555.104.794.78Net Income-$35.48M$151.51M$120.07M$225.60M7 Day Performance-10.81%-2.14%-1.90%-1.24%1 Month Performance7.69%-3.13%11.43%3.06%1 Year Performance-64.09%11.51%30.59%16.50% OptiNose Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTNOptiNose4.0257 of 5 stars$0.42-0.5%$3.00+614.1%-63.1%$63.36M$75.67M-1.50190High Trading VolumeAMLXAmylyx Pharmaceuticals4.2561 of 5 stars$4.16+1.0%$7.33+76.3%-70.7%$285.16M$196.49M-1.08200Short Interest ↓News CoveragePositive NewsITOSiTeos Therapeutics3.5018 of 5 stars$7.78+1.3%$25.25+224.6%-28.4%$284.24M$35M-2.4490Analyst ForecastLFCRLifecore Biomedical2.9045 of 5 stars$7.70+1.2%$10.00+29.9%+18.7%$283.57M$128.44M97.50690BNTCBenitec Biopharma3.6885 of 5 stars$12.13+3.1%$24.43+101.4%+277.8%$281.66M$80,000.000.0020Analyst RevisionFHTXFoghorn Therapeutics2.8809 of 5 stars$5.01-5.5%$16.00+219.4%-14.0%$278.52M$25.52M-2.76120Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeELDNEledon Pharmaceuticals2.9252 of 5 stars$4.53+3.4%$16.00+253.2%+196.6%$270.62MN/A-2.3310Positive NewsURGNUroGen Pharma3.8754 of 5 stars$11.47+1.1%$43.70+281.0%-28.4%$268.97M$82.71M-3.60200RZLTRezolute3.1803 of 5 stars$4.64+1.1%$24.13+419.9%+387.8%$268.86MN/A-3.6140AVIRAtea Pharmaceuticals3.0689 of 5 stars$3.16+7.8%$6.88+117.7%+5.6%$266.90M$351.37M-1.5370High Trading VolumeLRMRLarimar Therapeutics1.5678 of 5 stars$4.16-32.6%$20.43+391.1%+4.4%$265.45MN/A-3.5630Analyst RevisionNews CoveragePositive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies Amylyx Pharmaceuticals Alternatives iTeos Therapeutics Alternatives Lifecore Biomedical Alternatives Benitec Biopharma Alternatives Foghorn Therapeutics Alternatives Eledon Pharmaceuticals Alternatives UroGen Pharma Alternatives Rezolute Alternatives Atea Pharmaceuticals Alternatives Larimar Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OPTN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptiNose, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptiNose With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPTN Stock Alerts